ThirtyFiveBio emerges from stealth with presentation of first data from GPR35 Antagonist Program at AACR 2023. Third Company Created by M:M Bio and…
Latest News & Events
$49 Million Series B Financing to Advance Neoantigen Creation Approaches
Grey Wolf Therapeutics Closes Oversubscribed $49 Million Series B Financing to Advance First-of-its-Kind Neoantigen Creation Approaches Premier Syndicate of Life Science Industry…
Clinical Supply Agreement for new trail with Regeneron and Libtayo®
Grey Wolf Therapeutics Announces Clinical Supply Agreement with Regeneron for Trial Evaluating GRWD5769 in Combination with Libtayo® (cemiplimab) Combination of First-in-Class ERAP1…
GWT to present preclinical data on first-in-class ERAP1 Inhibitors at SITC
Grey Wolf Therapeutics, a biotechnology company spearheading a new therapeutic approach to immuno-oncology driven by targeted neoantigen generation, today announced the presentation of promising preclinical in vivo data on the company’s first-in-class inhibitors of ERAP1 at the 36th Annual Meeting of the Society for Immunotherapy of Cancer (SITC).
Grey Wolf Therapeutics completes £10 million ($14 million) series A financing
Grey Wolf Therapeutics completes £10 million ($14 million) series A financing with Andera Partners and Canaan to fund development of immuno-oncology therapies…
Pathios Therapeutics & Sygnature Discovery sign an innovative partnership
Pathios Therapeutics and Sygnature Discovery sign a strategic and innovative partnership to develop first in class therapies in autoimmune disease and immuno-oncology